A Phase 1 Study of NT-175 in People With Advanced Solid Tumors

Full Title

An Open-label, Phase 1, Multicentere Platform Study to Evaluate the Safety and Preliminary Anti-tumour activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants with Advanced Malignancies That Are Positive for the TP53 R175H Mutation

Purpose

Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:

• Non-small cell lung cancer
• Colorectal cancer
• Head and neck squamous cell carcinoma
• Pancreatic cancer
• Ovarian cancer
• Breast cancer

In addition, the cancers have a mutation (change) in the TP53 R175H gene. The study participants also have a molecule called HLA-A*02:01 on their cells.

NT-175 is made in a laboratory using your collected white blood cells (T cells). The T cells in NT-175 have been genetically changed so they target cells with mutated TP53 R175H. NT-175 is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Adam Schoenfeld’s office at 646-608-2091.